- Home
- ZEPP vs BLUE Comparison
ZEPP vs BLUE Comparison
Compare ZEPP & BLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEPP
- BLUE
- Stock Information
- Founded
- ZEPP 2013
- BLUE 1992
- Country
- ZEPP China
- BLUE United States
- Employees
- ZEPP N/A
- BLUE N/A
- Industry
- ZEPP Computer Manufacturing
- BLUE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZEPP Technology
- BLUE Health Care
- Exchange
- ZEPP Nasdaq
- BLUE Nasdaq
- Market Cap
- ZEPP 37.0M
- BLUE 36.9M
- IPO Year
- ZEPP N/A
- BLUE 2013
- Fundamental
- Price
- ZEPP $2.56
- BLUE $4.14
- Analyst Decision
- ZEPP
- BLUE Hold
- Analyst Count
- ZEPP 0
- BLUE 7
- Target Price
- ZEPP N/A
- BLUE $44.60
- AVG Volume (30 Days)
- ZEPP 25.8K
- BLUE 534.3K
- Earning Date
- ZEPP 05-19-2025
- BLUE 05-08-2025
- Dividend Yield
- ZEPP N/A
- BLUE N/A
- EPS Growth
- ZEPP N/A
- BLUE N/A
- EPS
- ZEPP N/A
- BLUE N/A
- Revenue
- ZEPP $182,603,000.00
- BLUE $83,807,000.00
- Revenue This Year
- ZEPP $758.69
- BLUE $218.58
- Revenue Next Year
- ZEPP N/A
- BLUE N/A
- P/E Ratio
- ZEPP N/A
- BLUE N/A
- Revenue Growth
- ZEPP N/A
- BLUE 184.12
- 52 Week Low
- ZEPP $2.06
- BLUE $3.56
- 52 Week High
- ZEPP $4.38
- BLUE $28.60
- Technical
- Relative Strength Index (RSI)
- ZEPP 44.08
- BLUE 41.65
- Support Level
- ZEPP $2.20
- BLUE $4.02
- Resistance Level
- ZEPP $2.66
- BLUE $5.15
- Average True Range (ATR)
- ZEPP 0.24
- BLUE 0.46
- MACD
- ZEPP -0.02
- BLUE -0.02
- Stochastic Oscillator
- ZEPP 42.48
- BLUE 8.57
About ZEPP Zepp Health Corporation
Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in two segments: Xiaomi Wearable Products and Self-branded products & others. The product portfolio includes smartwatches and fitness bands. The majority is from Self-branded products & other segments. It generates majority of the revenue from Xiaomi Wearable Products segment.
About BLUE bluebird bio Inc.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.